Novozymes 2022 Full Year Results & 2023 Outlook

Novozymes reported 9% organic sales growth for full year 2022 with solid EBIT margins of 26.4% before special items, driven by diversified performance across five business areas including bioenergy, household care, and food & beverages. The company outlined 2023 guidance of 4-7% organic sales growth with expected EBIT margins of 25-26% and announced a proposed combination with Chr. Hansen to create a leading global biosolutions partner.